AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
140.31
+0.28 (+0.20%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close140.03
Open140.16
Bid139.80 x 900
Ask140.56 x 900
Day's Range136.77 - 141.29
52 Week Range125.84 - 197.00
Volume2,086,823
Avg. Volume2,667,217
Market Cap46.333B
Beta (3Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-15.26
Earnings DateMay 7, 2019
Forward Dividend & Yield2.96 (2.15%)
Ex-Dividend Date2019-02-14
1y Target Est182.16
Trade prices are not sourced from all markets
  • Jerome Dodson Goes 2 for 2 in 1st Quarter
    GuruFocus.com2 days ago

    Jerome Dodson Goes 2 for 2 in 1st Quarter

    Guru invests in Dentsply Sirona, Sysco

  • Here's What We Think About Allergan plc's (NYSE:AGN) CEO Pay
    Simply Wall St.2 days ago

    Here's What We Think About Allergan plc's (NYSE:AGN) CEO Pay

    In 2014 Brent Saunders was appointed CEO of Allergan plc (NYSE:AGN). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big companies. Next, we'll consider growth that...

  • 50 Top Stocks That Billionaires Love
    Kiplinger2 days ago

    50 Top Stocks That Billionaires Love

    Do you want to invest like real billionaires do?Most billionaires obviously have much more money to burn than the average investor. And they also have enough cash in the bank to wait things out should their stock picks turn sour.Still, given the so-called "smart money's" resources and intimate connections with some of the companies they own, it wouldn't be a crazy idea to study the top stocks that billionaires and high-asset hedge funds are plowing their long-term capital into. Rich people often get perpetually richer for a reason.Here are 50 top stocks of the billionaire class. In all cases, these companies represent major holdings (anywhere between 5% and 100% of the portfolio) of at least one ultra-wealthy person or a large hedge fund. In many cases, these stock picks are heavily owned by multiple high-net-worth individuals and/or are high-conviction picks by several fund managers. And while several of these stocks are popular blue chips, others fall far off the radar of most investors. SEE ALSO: Millionaires in America 2019: All 50 States Ranked

  • Gilead Collaborates With Insitro to Develop NASH Therapies
    Zacks3 days ago

    Gilead Collaborates With Insitro to Develop NASH Therapies

    Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).

  • Allergan Falls as Supreme Court Dismisses Restasis Litigation
    Zacks4 days ago

    Allergan Falls as Supreme Court Dismisses Restasis Litigation

    Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

  • Could This Backing Help Allergan's CEO Retain His Chairman Role?
    Investor's Business Daily5 days ago

    Could This Backing Help Allergan's CEO Retain His Chairman Role?

    On Monday, a pair of proxy advisory firms backed Allergan's decision to allow Chief Executive Brent Saunders to also retain his chairman position. Shareholders are set to vote on May 1.

  • Proxy firms back Allergan in fight against Appaloosa
    Reuters5 days ago

    Proxy firms back Allergan in fight against Appaloosa

    The recommendations of Institutional Shareholder Services LP and Glass Lewis & Co against the proposal by Tepper's hedge fund Appaloosa LP give critical support to Allergan Chairman and CEO Brent Saunders before the drugmaker's shareholder meeting on May 1. "Their recommendations affirm our position that our plan to adopt separate Chair and CEO positions with the next leadership transition is the best approach for Allergan shareholders," Allergan said in a statement.

  • PR Newswire5 days ago

    New Study Showcases Economic and Community Impact of Allergan's Operations in Ohio

    CINCINNATI, April 15, 2019 /PRNewswire/ -- A new study by the University of Cincinnati Economics Center finds that the Ohio operations of biopharmaceutical company Allergan have a significant impact on the state's economy and communities. The study finds that the annual economic impact of Allergan's manufacturing and packaging facility in Cincinnati includes total output of $46.3 million and total earnings of $28.8 million.

  • U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents
    Reuters5 days ago

    U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

    The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe. The justices left in place a lower court ruling upholding the authority of a U.S. Patent and Trademark Office tribunal to decide the validity of patents covering Allergan's dry eye drug Restasis, refusing to hear the company's appeal.

  • PR Newswire5 days ago

    Leading Proxy Advisory Firms ISS and Glass Lewis Support ALL of Allergan Board's Voting Recommendations

    DUBLIN, April 15, 2019 /PRNewswire/ -- Allergan plc (AGN) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended that the Company's shareholders vote FOR all of the Company's proposals and AGAINST the dissident shareholder proposal ("Proposal No. 6") calling for the immediate separation of Chair and CEO roles at the Company's 2019 Annual Meeting of Stockholders, to be held on May 1, 2019.

  • Alkermes Reports Positive Data From Schizophrenia Study
    Zacks10 days ago

    Alkermes Reports Positive Data From Schizophrenia Study

    Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

  • Allergan Earns 2019 ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Sixth Consecutive Year
    PR Newswire10 days ago

    Allergan Earns 2019 ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Sixth Consecutive Year

    - Company Recognized for Continued Superior Energy Achievements - DUBLIN , April 10, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has ...

  • These 3 Value Stocks Are Absurdly Cheap Right Now
    Motley Fool11 days ago

    These 3 Value Stocks Are Absurdly Cheap Right Now

    Good bargains are hard to find in today's market. Here are a few overlooked stocks for you to capitalize on.

  • Reuters11 days ago

    Wynn ends A$10 billion acquisition talks with Australia's Crown Resorts

    Wynn's backtracking illustrates how media leaks of deal talks can test the resolve of potential acquirers. Crown shares jumped as much as 22 percent on the news to A$14.37, close to the $A14.75 per share level that Crown said Wynn's latest cash-and-stock offer valued the company. In this case, Wynn's inexperience with pursuing big deals also likely played a factor, some analysts added.

  • PR Newswire11 days ago

    Allergan to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast

    DUBLIN , April 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019 , prior to the open of U.S. Financial Markets. ...

  • Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World
    PR Newswire12 days ago

    Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

    "Allergan is proud to have undertaken one of the most far-reaching and authoritative studies ever conducted on the subject," says Brent Saunders, Chairman and CEO of Allergan. "As a company with worldwide awareness, reach, and brand affinity, we are in a unique position to identify and report on trends and drive change in the medical aesthetics category. To develop the report, Allergan tapped into more than 14,500 aesthetically conscious consumers and 1,300 aesthetic physicians in 18 countries, including the United States of America, Canada, Mexico, Brazil, the United Kingdom, Spain, France, Germany, Italy, Turkey, Russia, Saudi Arabia, India, China, Japan, South Korea, Taiwan and Australia.

  • Will Ironwood Suffer From Dependence on Linzess' Progress?
    Zacks15 days ago

    Will Ironwood Suffer From Dependence on Linzess' Progress?

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

  • Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
    Zacks15 days ago

    Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

    Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

  • Maker of Botox alternative turns toxin on crippling muscle disorder
    American City Business Journals16 days ago

    Maker of Botox alternative turns toxin on crippling muscle disorder

    Revance's Botox-like therapy could be used for a broad number of therapeutic as well as aesthetic uses, its leaders say. Regulators will have the final say.

  • Health Canada plans to suspend Allergan's breast implant license
    Reuters16 days ago

    Health Canada plans to suspend Allergan's breast implant license

    Health Canada plans to suspend the license for Allergan Plc's Biocell breast implant due to the risk of a rare cancer linked to such implants, the regulator said in a notice to the Botox-maker on Thursday. Breast augmentation using implants is a popular form of cosmetic surgery but regulators are studying textured implants, which have a rough surface, and their possible link to anaplastic large cell lymphoma (ALCL). Allergan has 15 days to respond to Health Canada, after which the regulator would suspend the license to sell the implants, if the company's response is not satisfactory, the agency said.

  • Reuters16 days ago

    Health Canada plans to suspend Allergan's breast implant license

    Health Canada plans to suspend the license for Allergan Plc's Biocell breast implant due to the risk of a rare cancer linked to such implants, the regulator said in a notice to the Botox-maker on Thursday. Breast augmentation using implants is a popular form of cosmetic surgery but regulators are studying textured implants, which have a rough surface, and their possible link to anaplastic large cell lymphoma (ALCL). Allergan has 15 days to respond to Health Canada, after which the regulator would suspend the license to sell the implants, if the company's response is not satisfactory, the agency said.

  • Editas (EDIT) Inks Cross Licensing Agreement with BlueRock
    Zacks16 days ago

    Editas (EDIT) Inks Cross Licensing Agreement with BlueRock

    Editas (EDIT) inks a research and cross licensing agreement with BlueRock Therapeutics, LP.